Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05951231 | Liver Transplantation After ex Vivo Liver Perfusion(EVOLVE) | not yet recruiting | N/A | 22 | Oslo University HospitalOTHER | 0 | Nov 1, 2023 | clinicaltrials |
| NCT05988372 | Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | not yet recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Nov 1, 2023 |
| clinicaltrials |
| NCT06110845 | CLinical Evaluation Of a comPuter Algorithm To Report BreAst cAncers (CLEOPATRAA)(CLEOPATRAA) | not yet recruiting | — | 800 | The Leeds Teaching Hospitals NHS TrustOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06112041 | The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0) | not yet recruiting | Phase 2 | 29 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06109896 | Clinical Stories and Psychological Experiences of Cancer Patients | not yet recruiting | — | 200 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Oct 31, 2023 | clinicaltrials |
| NCT06097455 | First in Human Study of the Infusion of ARI0003 Cells in Relapsed/Refractory to Treatment B-cell Aggressive Lymphoma(CARTD-BG-1) | not yet recruiting | Early Phase 1 | 40 | Fundacion Clinic per a la Recerca BiomédicaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06101966 | A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy | not yet recruiting | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102161 | Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) | not yet recruiting | Phase 3 | 286 | Fudan UniversityOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06097416 | Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer | not yet recruiting | Phase 3 | 100 | St. James's Hospital, IrelandOTHER | 0 | Oct 25, 2023 | clinicaltrials |
| NCT06099951 | Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy | not yet recruiting | Phase 2 | 53 | Sun Yat-sen UniversityOTHER | 0 | Oct 25, 2023 | clinicaltrials |
| NCT05923502 | (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL) | not yet recruiting | — | 200 | Ruijin HospitalOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06092242 | The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer | not yet recruiting | Phase 2 | 50 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06093165 | RE-irradiation of Diffuse MIdline Glioma paTients(REMIT) | not yet recruiting | N/A | 59 | Rigshospitalet, DenmarkOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06093568 | Delving Into Participation Trends in Renal Cell Carcinoma Studies | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06093594 | Investigating Participation Patterns Among Stage IV Melanoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06094868 | Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT06095167 | Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC | not yet recruiting | Phase 3 | 476 | Fujian Cancer HospitalOTHER_GOV | 1 | Oct 23, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT06086288 | Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC)(PANDORA) | not yet recruiting | Phase 2 | 35 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06079242 | Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer | not yet recruiting | — | 200 | GrandPharma (China) Co., Ltd.INDUSTRY | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | not yet recruiting | Phase 2 | 54 | Jin LiOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT05988697 | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib | not yet recruiting | — | 36 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Oct 12, 2023 | clinicaltrials |
| NCT06079723 | A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06076772 | Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients | not yet recruiting | — | 54 | Assiut UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT06066931 | Reconstruction of the Pelvic Floor and Perineal Wound After Rectal ELAPE | not yet recruiting | N/A | 150 | Kuban State Medical UniversityOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT06075238 | Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT | not yet recruiting | Phase 2 | 68 | Sichuan UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070246 | Navigating the Clinical Research Process for Lymphoma | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070259 | Insights Into Participating in Studies for Bone Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070272 | Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06070285 | Investigating Participation Patterns Among Recurrent Ovarian Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06067776 | Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer | not yet recruiting | Phase 1 | 36 | Jonathan RiessOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04790045 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens(LymBIO) | not yet recruiting | Phase 4 | 30 | Paolo GhiaOTHER | 0 | Oct 3, 2023 | clinicaltrials |
| NCT06062485 | Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06062589 | AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer | not yet recruiting | — | 18 | Peking University Third HospitalOTHER | 0 | Oct 2, 2023 | clinicaltrials |
| NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06061432 | Endoscopic Ultrasound- Guided Hartmann Reversal Procedure(EndoHARP) | not yet recruiting | N/A | 100 | Nicolaus Copernicus UniversityOTHER | 0 | Sep 29, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06039982 | A Diagnostic Nomogram for Predicting Vaginal Invasion in Cervical Cancer | not yet recruiting | — | 100 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06053996 | Hepatopulmonary Radio-sterilization With Immunotherapy(TROS-8) | not yet recruiting | N/A | 44 | Sheba Medical CenterOTHER_GOV | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06055114 | Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age | not yet recruiting | — | 300 | Lin YuanOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06049472 | Patient Perspectives in Mantle Cell Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06049485 | Assessing the Experience of Patients Undergoing Follicular Lymphoma Clinical Research | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06047535 | Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. | not yet recruiting | Phase 4 | 62 | SciClone PharmaceuticalsINDUSTRY | 0 | Sep 21, 2023 | clinicaltrials |
| NCT06041490 | Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation | not yet recruiting | Phase 2 | 88 | Peking Union Medical College HospitalOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT06039033 | Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06039046 | Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT06039891 | Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 55 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2023 | clinicaltrials |
| NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer(SPECTRA) | not yet recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2023source: clinicaltrials